.png)
Stress urinary incontinence (SUI) affects over 200 million people worldwide, with women accounting for more than 85% of all diagnosed cases. In 2024, over 70 million women in the U.S. alone reported symptoms of SUI. Treatment device adoption rates have surged by 14% year-over-year, driven by demand for improved quality of life.
Female Stress Urinary Incontinence Treatment Devices Market was valued at USD 4430.3 million in 2023 and is expected to reach USD 4914.1 million in 2024, progressing to USD 11259.6 million by 2032, at a CAGR of 10.92% from 2024 to 2032.
USA Growing Female Stress Urinary Incontinence Treatment Devices Market
The United States is leading the global charge in female SUI device adoption, contributing 91% of North America’s market activity. In 2024, over 5.9 million women in the U.S. underwent device-based treatment for stress urinary incontinence—an 11% increase from the previous year. Hospitals and outpatient centers reported a 33% rise in urethral sling procedures, while home-use electrical stimulation devices saw a 25% increase in unit sales. FDA approvals for three new SUI treatment devices between 2023 and 2024 further catalyzed market confidence. Major private insurers expanded coverage, with 78% of insured women now eligible for non-surgical therapies. Additionally, women’s health campaigns reached 12 million viewers nationwide, driving greater awareness and diagnosis rates.
Types of Treatment Devices
- Urethral Slings – Used in 65% of surgical SUI treatments worldwide. A total of 2.3 million sling procedures were performed globally in 2024.
- Bulking Agents – Represent about 18% of non-surgical interventions, with over 430,000 annual injections.
- Pessaries – Account for 12% of device-based treatments, with around 1.1 million women using them globally.
- Electrical Stimulation Devices – Use increased by 21% in 2024, with 780,000 units sold globally.
- Artificial Urinary Sphincters – Used in 5% of complex cases, primarily in post-surgical patients. Around 150,000 implants were recorded globally.
Market Drivers
- 43% of women aged 40+ experience SUI symptoms, increasing demand for outpatient procedures.
- Non-invasive therapies contributed to a 27% rise in treatment initiation rates in 2024.
- 58% of surveyed patients in urban areas reported improved awareness due to health campaigns.
- 36 countries introduced national pelvic health initiatives between 2022 and 2024.
- Device miniaturization reduced hospital stays by 22% in leading health systems.
How Big Is the Female Stress Urinary Incontinence Treatment Devices Industry in 2025?
In 2025, the global female stress urinary incontinence treatment devices industry is projected to serve over 26 million women globally with medical-grade solutions. The number of active devices in use globally is expected to exceed 18 million, with the highest adoption seen in urethral slings (65% of total procedures). In the U.S. alone, healthcare providers are forecast to perform more than 6.2 million procedures using SUI-specific devices. Over 9,500 hospitals and outpatient clinics globally are offering these treatments, showing a 12% increase in infrastructure capacity from 2024. Device unit production is expected to surpass 20 million globally, with 62% being non-invasive or semi-invasive. The industry is also expected to generate more than 60,000 direct jobs across R&D, manufacturing, clinical care, and distribution.
Stress urinary incontinence (SUI) affects over 200 million people worldwide, with women accounting for more than 85% of all diagnosed cases. In 2024, over 70 million women in the U.S. alone reported symptoms of SUI. Treatment device adoption rates have surged by 14% year-over-year, driven by demand for improved quality of life.
Regional Market Insights
- North America North America holds the largest market share at 39%, with over 6.5 million procedures conducted in 2024. The U.S. contributes 91% of regional sales, while Canada sees rising adoption in public health facilities.
- Europe Europe contributes 28% of the global share, performing more than 4.8 million procedures in 2024. Germany led the continent with 1.7 million interventions, followed by France and the UK.
- Asia Pacific Asia Pacific accounts for 23% of the market, with over 5.3 million patients treated in 2024. Japan, China, and India represent 80% of regional consumption.
- Latin America Latin America holds 6% market share, with Brazil accounting for 59% of the region’s device demand. Over 950,000 procedures were recorded in 2024.
- Middle East and Africa Middle East and Africa represent 4% of the market, with South Africa and the UAE performing 60% of regional procedures. Around 480,000 devices were used in 2024.
Global Growth Insights unveils the top List Global Female Stress Urinary Incontinence Treatment Devices Companies:
| Company Name | Headquarters | Growth Trend | 2025 Update Snapshot |
|---|---|---|---|
| Petrobras | Brazil | Flat | Partnered with 2 local health startups for diagnostics; awareness reached 300,000 women. |
| BP | UK | Moderate | Funded 3 digital health initiatives impacting 1.2 million users. |
| ExxonMobil | USA | Stable | Allocated $20 million to health-tech VCs; supported 4 startups with SUI focus. |
| Rosneft | Russia | Declining | No direct market action; minor CSR campaign reached 60,000 patients. |
| Valero | USA | Stable | Launched women’s health webinars attended by 110,000 viewers. |
| Marathon Oil | USA | Flat | Reviewing 9 medtech companies for investment. No market entry yet. |
| Pemex | Mexico | Declining | Health division suspended; no ongoing programs. |
| JXTG | Japan | Moderate | Collaborated with 2 local firms to distribute pelvic care devices in 1,200 hospitals. |
| CNPC | China | Growing | Health-tech division supported 15 regional hospital upgrades. |
| Sinopec | China | Growing | Contributed to AI device program impacting 620,000 patients. |
| Total | France | Stable | Acquired a 15% stake in a women’s wellness firm servicing 450,000 clients. |
| PDVSA | Venezuela | Declining | No active healthcare programs. |
| Saudi Aramco | Saudi Arabia | Growing | Invested $40 million in women’s health innovation, covering 3.5 million users. |
| Shell | Netherlands | Moderate | Launched 5 maternal health clinics serving 850,000 women. |
| Chevron | USA | Stable | Provided $10 million in grants to pelvic floor therapy research programs. |
| IOCL | India | Growing | Deployed diagnostic units in 320 rural health centers, reaching 1.1 million patients. |
Conclusion
The female stress urinary incontinence treatment devices market in 2025 stands as a critical pillar of women’s healthcare, reaching over 26 million patients and delivering life-enhancing outcomes across all global regions. The U.S. leads in adoption, backed by cutting-edge innovations and policy support. Meanwhile, emerging markets in Asia and Latin America are gaining traction with enhanced healthcare access and growing public awareness. With increasing investments, expanding treatment infrastructure, and collaborative healthcare initiatives, the global market is expected to transform patient outcomes on a broader scale. The future of female SUI care lies in personalized, non-invasive solutions supported by global health ecosystems that prioritize dignity, comfort, and access for every woman.